The product was developed using XOMA's patented targeted gelonin fusion technology, which is also available for licensing. XOMA and the Hyland Immuno Division of Baxter Healthcare are developing this systemic formulation of rBPI-21 for multiple indications. Current work is directed at optimizing a formulation for clinical testing. It has been initially formulated as an injectable product targeting systemic fungal infections. XOMA is currently completing the necessary preclinical work to support filing an IND, and is seeking partners for clinical development and commercialization of the product.
Antiangiogenic compounds are in preclinical development with an initial focus on retinal disorders.
XOMA is in discussions with potential partners. To listen to the live call, please go to the Web site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. A replay will begin shortly after the call has ended and will be available for 30 days. XOMA develops and manufactures antibody and protein-derived biopharmaceuticals in its Berkeley and Santa Monica, California facilities. Statements made in this news release related to the timing and results of clinical trials, FDA regulatory process, release of data and other aspects of product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.